Precision oncology in cholangiocarcinoma integrates molecular taxonomy testing strategies and treatment sequencing.
Cholangiocarcinoma (CCA) is biologically heterogeneous, and timely molecular profiling is increasingly critical for treatment selection in unresectable, recurrent, or metastatic disease. This pragmatic framework aims to improve the consistency, speed, and clinical actionability of precision oncology in advanced CCA.
Cholangiocarcinoma (CCA) is biologically heterogeneous, and timely molecular profiling is increasingly critical for treatment selection in unresectable, recurrent, or metastatic disease. This pragmatic framework aims to improve the consistency, speed, and clinical actionability of precision oncology in advanced CCA.
What the study was
- Study design
- Review
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Discover oncology
Why it surfaced
Low-signal Early cancer detection entry (Review design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.